Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

The art of medicine: our role as patient advocates.

Weiden PL.

J Clin Oncol. 2012 Nov 1;30(31):3893-4. doi: 10.1200/JCO.2012.43.1908. Epub 2012 Jun 11. No abstract available.

PMID:
22689808
2.

Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma.

Muntz HG, Malpass TW, McGonigle KF, Robertson MD, Weiden PL.

Cancer. 2008 Aug 1;113(3):490-6. doi: 10.1002/cncr.23576.

3.

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.

Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, Goris ML, Picozzi VJ, Axworthy DB, Breitz HB, Sims RB, Ghalie RG, Shen S, Meredith RF.

Blood. 2004 Jul 1;104(1):227-36. Epub 2004 Mar 2.

PMID:
14996706
4.
5.

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).

Weiden PL, Breitz HB.

Crit Rev Oncol Hematol. 2001 Oct;40(1):37-51.

PMID:
11578915
6.

Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.

Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC.

J Clin Oncol. 2001 Jul 15;19(14):3422-33.

PMID:
11454891
7.

Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.

Breitz HB, Fisher DR, Goris ML, Knox S, Ratliff B, Murtha AD, Weiden PL.

Cancer Biother Radiopharm. 1999 Oct;14(5):381-95.

PMID:
10850323
8.

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.

Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, Stone D, Axworthy D, Fisher D, Reno J.

Cancer Biother Radiopharm. 2000 Feb;15(1):15-29.

PMID:
10740649
9.

Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.

Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM.

Clin Cancer Res. 2000 Feb;6(2):406-14.

10.

Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin.

Breitz HB, Weiden PL, Beaumier PL, Axworthy DB, Seiler C, Su FM, Graves S, Bryan K, Reno JM.

J Nucl Med. 2000 Jan;41(1):131-40.

11.
12.

An Asian man with enlarged glands.

Weiden PL, Bauermeister DE, Fatta EA.

Lancet. 1998 Apr 11;351(9109):1098. No abstract available.

PMID:
9660580
13.
14.

Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation.

Chen CS, Seidel K, Armitage JO, Fay JW, Appelbaum FR, Horowitz MM, Shpall EJ, Weiden PL, Antman KS, Champlin RE, Kersey JH, Sullivan KM.

Biol Blood Marrow Transplant. 1997 Dec;3(6):331-40.

PMID:
9502301
15.

Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy.

Breitz HB, Tyler A, Bjorn MJ, Lesley T, Weiden PL.

Clin Nucl Med. 1997 Sep;22(9):615-20.

PMID:
9298295
17.

High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.

Brunvand MW, Bensinger WI, Soll E, Weaver CH, Rowley SD, Appelbaum FR, Lilleby K, Clift RA, Gooley TA, Press OW, Fefer A, Storb R, Sanders JE, Martin PL, Chauncey T, Maziarz RT, Zuckerman N, Montgomery P, Dorn R, Weiden PL, Demirer T, Holmberg LA, Schiffman K, McSweeney PA, Buckner CD, et al.

Bone Marrow Transplant. 1996 Jul;18(1):131-41.

PMID:
8832006
18.
19.

Perceptions of cancer patients and their physicians involved in phase I clinical trials.

Weiden PL, Appelbaum JW.

J Clin Oncol. 1995 Sep;13(9):2472. No abstract available.

PMID:
7666108
20.

Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody.

Breitz HB, Durham JS, Fisher DR, Weiden PL, DeNardo GL, Goodgold HM, Nelp WB.

J Nucl Med. 1995 May;36(5):754-61.

22.

Human anti-mouse antibody suppression with cyclosporin A.

Weiden PL, Wolf SB, Breitz HB, Appelbaum JW, Seiler CA, Mallett R, Bjorn MJ, Su FM, Fer MF, Salk D.

Cancer. 1994 Feb 1;73(3 Suppl):1093-7.

PMID:
8306252
23.

Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10.

Weiden PL, Breitz HB, Seiler CA, Bjorn MJ, Ratliff BA, Mallett R, Beaumier PL, Appelbaum JW, Fritzberg AR, Salk D.

J Nucl Med. 1993 Dec;34(12):2111-9.

24.

Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials.

Breitz HB, Fisher DR, Weiden PL, Durham JS, Ratliff BA, Bjorn MJ, Beaumier PL, Abrams PG.

J Nucl Med. 1993 Jun;34(6):908-17.

25.

Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.

Breitz HB, Weiden PL, Vanderheyden JL, Appelbaum JW, Bjorn MJ, Fer MF, Wolf SB, Ratliff BA, Seiler CA, Foisie DC, et al.

J Nucl Med. 1992 Jun;33(6):1099-109.

27.

Do peroperative blood transfusions increase the risk of cancer recurrence?

Weiden PL.

Eur J Cancer. 1990;26(9):987-9. Review. No abstract available.

PMID:
2149027
28.

High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma.

Petersen FB, Appelbaum FR, Bigelow CL, Buckner CD, Clift RA, Sanders JE, Storb R, Sullivan KM, Weiden PL, Fefer A, et al.

Bone Marrow Transplant. 1989 Sep;4(5):483-8.

PMID:
2676043
29.

Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia.

Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, et al.

Blood. 1989 May 1;73(6):1720-8. Erratum in: Blood 1989 Aug 15;74(3):1180.

PMID:
2653460
30.

Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms.

Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J, et al.

N Engl J Med. 1989 Mar 30;320(13):828-34.

PMID:
2648143
31.
32.

Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease.

Martin PJ, Hansen JA, Torok-Storb B, Moretti L, Press O, Storb R, Thomas ED, Weiden PL, Vitetta ES.

Bone Marrow Transplant. 1988 Sep;3(5):437-44. Erratum in: Bone Marrow Transplant 1989 Mar;4(2):215.

PMID:
2973360
33.

Approaches to preventing or reversing platelet alloimmunization using animal models.

Slichter SJ, Weiden PL, Kane PJ, Storb RF.

Transfusion. 1988 Mar-Apr;28(2):103-8.

PMID:
3354038
34.

Perioperative blood transfusion does not increase the risk of colorectal cancer recurrence.

Weiden PL, Bean MA, Schultz P.

Cancer. 1987 Aug 15;60(4):870-4.

PMID:
3594405
35.

Cardiotoxicity of 5-fluorouracil.

Collins C, Weiden PL.

Cancer Treat Rep. 1987 Jul-Aug;71(7-8):733-6. Review.

PMID:
3300968
36.

Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin.

Storb R, Weiden PL, Sullivan KM, Appelbaum FR, Beatty P, Buckner CD, Clift RA, Doney KC, Hansen J, Martin PJ, et al.

Blood. 1987 Jul;70(1):116-21.

PMID:
3297199
37.

Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.

Tallman MS, Appelbaum FR, Amos D, Goldberg RS, Livingston RB, Mortimer J, Weiden PL, Thomas ED.

J Clin Oncol. 1987 Jun;5(6):918-26.

PMID:
3585446
38.

Marrow transplantation for acute nonlymphocytic leukemia following therapy for Hodgkin's disease.

Sargur M, Buckner CD, Appelbaum FR, Stewart P, Deeg HJ, Weiden PL, Sullivan KM, Fefer A, Thomas ED.

J Clin Oncol. 1987 May;5(5):731-4.

PMID:
3553436
40.

Prevention of graft-versus-host disease by immunosuppressive agents after transplantation of DLA-nonidentical canine marrow.

Storb R, Kolb HJ, Deeg HJ, Weiden PL, Appelbaum F, Graham TC, Thomas ED.

Bone Marrow Transplant. 1986 Dec;1(2):167-77.

PMID:
3332131
41.

Canine platelet alloimmunization: the role of donor selection.

Slichter SJ, O'Donnell MR, Weiden PL, Storb R, Schroeder ML.

Br J Haematol. 1986 Aug;63(4):713-27.

PMID:
3730294
42.

Second marrow infusion for poor graft function after allogeneic marrow transplantation.

Bolger GB, Sullivan KM, Storb R, Witherspoon RP, Weiden PL, Stewart P, Sanders J, Meyers JD, Martin PJ, Doney KC, et al.

Bone Marrow Transplant. 1986 May;1(1):21-30.

PMID:
3332116
43.

Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer.

Weiden PL, Einstein AB, Rudolph RH.

Cancer Treat Rep. 1985 Nov;69(11):1253-5.

PMID:
4092189
44.

Autologous marrow transplantation as consolidation therapy for canine lymphoma: efficacy and toxicity of various regimens of total body irradiation.

Deeg HJ, Appelbaum FR, Weiden PL, Hackman RC, Graham TC, Storb RC.

Am J Vet Res. 1985 Sep;46(9):2016-8.

PMID:
3901841
45.

Marrow transplant studies in dogs with malignant lymphoma.

Appelbaum FR, Deeg HJ, Storb R, Self S, Graham TC, Sale GE, Weiden PL.

Transplantation. 1985 May;39(5):499-504.

PMID:
3887690
46.

Olfactory neuroblastoma. Chemotherapy and radiotherapy for extensive disease.

Weiden PL, Yarington CT Jr, Richardson RG.

Arch Otolaryngol. 1984 Nov;110(11):759-60.

PMID:
6541469
47.

Thymosin fraction 5 does not accelerate reconstitution of immunologic reactivity after human marrow grafting.

Witherspoon RP, Hersman J, Storb R, Ochs H, Goldstein AL, McClure J, Noel D, Weiden PL, Thomas ED.

Br J Haematol. 1983 Dec;55(4):595-608.

PMID:
6367801
48.

Marrow transplantation for patients with acute lymphoblastic leukemia: a long-term follow-up.

Thomas ED, Sanders JE, Flournoy N, Johnson FL, Buckner CD, Clift RA, Fefer A, Goodell BW, Storb R, Weiden PL.

Blood. 1983 Nov;62(5):1139-41.

PMID:
6354306
49.

Allogeneic bone marrow transplantation.

Weiden PL.

Crit Rev Clin Lab Sci. 1983;19(3):173-86. Review.

PMID:
6373140
50.

Cyclosporin-A abrogates transfusion-induced sensitization and prevents marrow graft rejection in DLA-identical canine littermates.

Storb R, Deeg HJ, Atkinson K, Weiden PL, Sale G, Colby R, Thomas ED.

Blood. 1982 Aug;60(2):524-6.

PMID:
7046849

Supplemental Content

Loading ...
Support Center